{"product_id":"orion-value-chain-analysis","title":"Orion Value Chain Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Value Chain Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Orion Value Chain Analysis gives you a structured view of how the company creates value through its support and primary activities. This page already shows a real preview of the actual report content, so you can review the format before buying. Purchase the full version to access the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eupport Activities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirm Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrion manages firm infrastructure from a central corporate office in Finland, which helps keep governance tight across its global pharma operations and supports compliance with FDA and EMA rules. In 2025, this structure backed a strong balance sheet, with an equity ratio above 60%, giving Orion room to fund long-cycle drug development and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Resource Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Orion employed about 3,650 people, and its human resource management centers on hiring and keeping high-level researchers and quality control experts. That matters because Orion’s drug pipeline spans complex neurological and oncological therapies, where one missed process step can delay batch release or raise compliance risk. Strong retention also protects know-how at its specialized manufacturing hub, where skilled talent directly supports quality, speed, and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrion Corporation's technology development is built around an R\u0026amp;D spend of about 12% to 15% of annual net revenue, with the 2025 focus still on medicinal chemistry and proprietary inhaler devices. This is the main engine behind its clinical trial pipeline and patent-protected products, which support future profit growth. In pharma, each step in R\u0026amp;D can stretch over years, so this spend is a core value-chain driver, not a cost center.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn Orion's procurement, 2025 sourcing should secure active pharmaceutical ingredients and specialty chemical precursors through vetted global suppliers, with dual-sourcing on critical inputs to cut delay risk. Tight supplier audits and ESG checks matter because a single API disruption can halt batches and lift costs fast; pharma supply chains still face high shortage pressure. For life-saving specialty drugs, disciplined buying protects quality, steadies output, and supports margin control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Support-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrion’s Strong Support Base Keeps R\u0026amp;D, Quality, and Supply Secure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrion’s support activities in 2025 stayed centered on tight Finland-led governance, with an equity ratio above 60% supporting compliance and long-term R\u0026amp;D. It employed about 3,650 people, and that specialist talent base backed quality, regulatory control, and batch reliability. R\u0026amp;D still ran at about 12% to 15% of net revenue, while procurement focused on vetted, dual-sourced inputs to reduce API disruption risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupport activity\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003cth\u003eValue-chain role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirm infrastructure\u003c\/td\u003e\n\u003ctd\u003eEquity ratio above 60%\u003c\/td\u003e\n\u003ctd\u003eFunds compliance and planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman resources\u003c\/td\u003e\n\u003ctd\u003eAbout 3,650 employees\u003c\/td\u003e\n\u003ctd\u003eProtects specialist know-how\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology development\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D at 12% to 15% of net revenue\u003c\/td\u003e\n\u003ctd\u003eDrives pipeline and patents\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement\u003c\/td\u003e\n\u003ctd\u003eDual-sourced critical inputs\u003c\/td\u003e\n\u003ctd\u003eLowers shortage and delay risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nMaps Orion’s support and primary activities to show how the company creates value and competitive advantage\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nRelieves value chain planning pain with a clear, editable snapshot of primary and support activities.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erimary Activities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInbound Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrion’s inbound logistics in 2025 centers on strict quarantine and quality testing for incoming raw materials and biological agents before they enter pharma production. The company also relies on high-frequency logistics for temperature-sensitive inputs, which keeps specialized facilities supplied and production moving without avoidable stops. One missed cold-chain handoff can shut down a batch, so inventory control is a direct production risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Orion's operations were anchored by six manufacturing sites in Finland, where automation and strict GMP standards supported output for both human and animal drugs. This setup gave Orion scale in core products, especially Nubeqa, which reached EUR 1.5 billion in worldwide sales in 2025. Easyhaler also stayed a key volume driver in respiratory care, helping spread fixed plant costs across more batches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutbound Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrion's outbound logistics moved finished pharmaceuticals to more than 100 countries in 2025, using a cold-chain network to protect sensitive biological compounds. In Northern Europe, leading wholesalers support fast local delivery, while Orion's own channels handle other markets. This setup helps keep availability high and lowers the risk of product degradation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrion’s marketing and sales rely on a dual model: its own European sales force and global partners such as Bayer and MSD, which extends reach without building every channel in-house. In 2025, this matters most in niche medicines, where clinical data drives physician trust and faster uptake. The company uses study results and partner networks to protect share in tightly defined segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrion's service activity centers on post-sale pharmacovigilance and medical information support, helping patients and healthcare practitioners with drug interactions, dosing, and efficacy questions. Active safety monitoring and technical device support create fast feedback loops that can flag adverse events early and reduce compliance risk. This service layer strengthens trust and repeat use, which matters in a market where late-stage safety issues can quickly hurt sales and reputation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/VALUE-CHAIN-Content-Primary-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrion’s 2025 pharma engine spans 6 sites and 100+ countries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrion’s primary activities in 2025 ran from strict raw-material quarantine to six Finnish manufacturing sites, where GMP and automation supported output for human and animal medicines. Nubeqa led with EUR 1.5 billion in worldwide sales, while Easyhaler stayed a key volume driver. Finished drugs moved to 100+ countries through cold-chain logistics, partner sales, and post-sale safety monitoring.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNubeqa sales\u003c\/td\u003e\n\u003ctd\u003eEUR 1.5 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets served\u003c\/td\u003e\n\u003ctd\u003e100+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eOrion Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Orion Value Chain Analysis preview you see here is the exact document you’ll receive after purchase. No sample content, no placeholders—just the same professional, ready-to-use report. Once you complete checkout, the full Value Chain Analysis is unlocked immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Model Business Canvas","offers":[{"title":"Default Title","offer_id":53359609905494,"sku":"orion-value-chain-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1023\/3954\/3382\/files\/orion-value-chain-analysis.webp?v=1777699542","url":"https:\/\/modelbusinesscanvas.com\/products\/orion-value-chain-analysis","provider":"Model Business Canvas","version":"1.0","type":"link"}